Life Molecular Imaging GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- -
- Established
- 2011-01-01
- Employees
- -
- Market Cap
- -
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Life Molecular Imaging GmbH
- Target Recruit Count
- 15
- Registration Number
- NCT06790394
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧King's College London, London, United Kingdom
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
Phase 1
Completed
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Drug: [18F]-PI2620
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Life Molecular Imaging GmbH
- Target Recruit Count
- 15
- Registration Number
- NCT05187546
- Locations
- 🇩🇪
Ludwig-Maximilians-Universität München, Munich, Germany
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Phase 3
Recruiting
- Conditions
- Cardiac AmyloidosisAL AmyloidosisATTR Amyloidosis
- Interventions
- Drug: [18F]florbetaben
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Life Molecular Imaging GmbH
- Target Recruit Count
- 200
- Registration Number
- NCT05184088
- Locations
- 🇺🇸
St Luke's Hospital, Kansas City, Kansas, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
Phase 1
Completed
- Conditions
- Progressive Supranuclear PalsyAlzheimer Disease
- Interventions
- Drug: [18F]-PI2620
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Life Molecular Imaging GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT04715750
- Locations
- 🇩🇪
Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
© Copyright 2025. All Rights Reserved by MedPath